SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
The group American Commitment is running ads in several states attacking Democrats' plan to lower prescription drug prices. (Photo: Screengrab/American Commitment)
Big Pharma Flooding Airwaves With Disinformation to Kill Drug Price Reform
"Powerful interest groups out there don't want this legislation to succeed, so they're pouring dark money into efforts to stop it," said one Democratic senator.
Jul 29, 2022
While its thousands of lobbyists work fervently on Capitol Hill, the pharmaceutical industry is flooding the airwaves in several states with deceptive ads in a last-ditch campaign to block Senate Democrats' plan to curb the unchecked pricing power of drug corporations.
Included as part of a reconciliation package negotiated by Sen. Joe Manchin (D-W.Va.) and Senate Majority Leader Chuck Schumer (D-N.Y.), the proposal would require Medicare to negotiate the prices of a small number of drugs directly with pharmaceutical companies, which can currently drive up costs as they please--boosting their profits at the expense of patients.
"We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
The measure would also cap out-of-pocket medicine costs at $2,000 a year for recipients of Medicare Part D, the prescription drug benefit provided through private plans approved by the federal government.
The drug industry--which has repeatedly fought off price regulation attempts in recent decades--has lashed out furiously against Democrats' plan, even though it is in some ways significantly weaker than a proposal that the House passed last year. Republicans bankrolled by Big Pharma are also working to tank the bill.
Roll Call reported Friday that the "Pharmaceutical Research and Manufacturers of America (PhRMA), the National Association of Manufacturers, and a group called American Commitment have collectively spent millions of dollars on ads in July" to attack Democrats' proposal, key parts of which are overwhelmingly popular with the American public.
"We're going to use every tool in the toolbox to relentlessly educate lawmakers about the flaws in this bill," declared Stephen Ubl, president of PhRMA, the nation's leading drug industry trade group.
American Commitment, a nonprofit with ties to the Koch Brothers, launched a new seven-figure ad buy on Thursday, targeting audiences in Washington, D.C. as well as West Virginia, Nevada, and Georgia.
The ads, which can be viewed in full on American Commitment's website, recycle the false and repeatedly debunked claim that Democrats' bill would cut "nearly $300 billion from Medicare," distorting the Congressional Budget Office's estimate that the legislation would save the federal government roughly $290 billion over ten years.
The American Prosperity Alliance, a dark money group, is running similarly misleading ads.
Sen. Catherine Cortez Masto (D-Nev.) responded directly to the ads--one of which attacks her directly--in a speech on the Senate floor earlier this week, noting that the 30-second spots led hundreds of constituents to call her office seeking an explanation.
"They were anxious and alarmed over a deliberately misleading ad that is running on TV, on Facebook, and via a text campaign," said Cortez Masto. "In Reno this past weekend, Nevadans came up to me because they were concerned about these false accusations. This ad incorrectly claims that I support a bill that would strip $300 billion dollars from Medicare. This couldn't be further from the truth."
"Powerful interest groups out there don't want this legislation to succeed, so they're pouring dark money into efforts to stop it," the senator continued. "Well, let me just say this: it won't work."
In an analysis of Democrats' proposal published Wednesday, the Kaiser Family Foundation (KFF) concluded that the bill has the potential to "limit annual increases in drug prices for people with Medicare and private insurance" and "provide substantial financial protection to people on Medicare with high out-of-pocket costs."
The precise impact of the legislation, KFF stressed, will depend on which prescription drugs Medicare chooses to negotiate. A separate KFF analysis released last year found that a small number of drugs make up a major share of Medicare's prescription drug spending.
"We are inches from the goal line," David Mitchell, the founder of Patients for Affordable Drugs, tweeted Friday. "We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
While its thousands of lobbyists work fervently on Capitol Hill, the pharmaceutical industry is flooding the airwaves in several states with deceptive ads in a last-ditch campaign to block Senate Democrats' plan to curb the unchecked pricing power of drug corporations.
Included as part of a reconciliation package negotiated by Sen. Joe Manchin (D-W.Va.) and Senate Majority Leader Chuck Schumer (D-N.Y.), the proposal would require Medicare to negotiate the prices of a small number of drugs directly with pharmaceutical companies, which can currently drive up costs as they please--boosting their profits at the expense of patients.
"We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
The measure would also cap out-of-pocket medicine costs at $2,000 a year for recipients of Medicare Part D, the prescription drug benefit provided through private plans approved by the federal government.
The drug industry--which has repeatedly fought off price regulation attempts in recent decades--has lashed out furiously against Democrats' plan, even though it is in some ways significantly weaker than a proposal that the House passed last year. Republicans bankrolled by Big Pharma are also working to tank the bill.
Roll Call reported Friday that the "Pharmaceutical Research and Manufacturers of America (PhRMA), the National Association of Manufacturers, and a group called American Commitment have collectively spent millions of dollars on ads in July" to attack Democrats' proposal, key parts of which are overwhelmingly popular with the American public.
"We're going to use every tool in the toolbox to relentlessly educate lawmakers about the flaws in this bill," declared Stephen Ubl, president of PhRMA, the nation's leading drug industry trade group.
American Commitment, a nonprofit with ties to the Koch Brothers, launched a new seven-figure ad buy on Thursday, targeting audiences in Washington, D.C. as well as West Virginia, Nevada, and Georgia.
The ads, which can be viewed in full on American Commitment's website, recycle the false and repeatedly debunked claim that Democrats' bill would cut "nearly $300 billion from Medicare," distorting the Congressional Budget Office's estimate that the legislation would save the federal government roughly $290 billion over ten years.
The American Prosperity Alliance, a dark money group, is running similarly misleading ads.
Sen. Catherine Cortez Masto (D-Nev.) responded directly to the ads--one of which attacks her directly--in a speech on the Senate floor earlier this week, noting that the 30-second spots led hundreds of constituents to call her office seeking an explanation.
"They were anxious and alarmed over a deliberately misleading ad that is running on TV, on Facebook, and via a text campaign," said Cortez Masto. "In Reno this past weekend, Nevadans came up to me because they were concerned about these false accusations. This ad incorrectly claims that I support a bill that would strip $300 billion dollars from Medicare. This couldn't be further from the truth."
"Powerful interest groups out there don't want this legislation to succeed, so they're pouring dark money into efforts to stop it," the senator continued. "Well, let me just say this: it won't work."
In an analysis of Democrats' proposal published Wednesday, the Kaiser Family Foundation (KFF) concluded that the bill has the potential to "limit annual increases in drug prices for people with Medicare and private insurance" and "provide substantial financial protection to people on Medicare with high out-of-pocket costs."
The precise impact of the legislation, KFF stressed, will depend on which prescription drugs Medicare chooses to negotiate. A separate KFF analysis released last year found that a small number of drugs make up a major share of Medicare's prescription drug spending.
"We are inches from the goal line," David Mitchell, the founder of Patients for Affordable Drugs, tweeted Friday. "We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
While its thousands of lobbyists work fervently on Capitol Hill, the pharmaceutical industry is flooding the airwaves in several states with deceptive ads in a last-ditch campaign to block Senate Democrats' plan to curb the unchecked pricing power of drug corporations.
Included as part of a reconciliation package negotiated by Sen. Joe Manchin (D-W.Va.) and Senate Majority Leader Chuck Schumer (D-N.Y.), the proposal would require Medicare to negotiate the prices of a small number of drugs directly with pharmaceutical companies, which can currently drive up costs as they please--boosting their profits at the expense of patients.
"We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
The measure would also cap out-of-pocket medicine costs at $2,000 a year for recipients of Medicare Part D, the prescription drug benefit provided through private plans approved by the federal government.
The drug industry--which has repeatedly fought off price regulation attempts in recent decades--has lashed out furiously against Democrats' plan, even though it is in some ways significantly weaker than a proposal that the House passed last year. Republicans bankrolled by Big Pharma are also working to tank the bill.
Roll Call reported Friday that the "Pharmaceutical Research and Manufacturers of America (PhRMA), the National Association of Manufacturers, and a group called American Commitment have collectively spent millions of dollars on ads in July" to attack Democrats' proposal, key parts of which are overwhelmingly popular with the American public.
"We're going to use every tool in the toolbox to relentlessly educate lawmakers about the flaws in this bill," declared Stephen Ubl, president of PhRMA, the nation's leading drug industry trade group.
American Commitment, a nonprofit with ties to the Koch Brothers, launched a new seven-figure ad buy on Thursday, targeting audiences in Washington, D.C. as well as West Virginia, Nevada, and Georgia.
The ads, which can be viewed in full on American Commitment's website, recycle the false and repeatedly debunked claim that Democrats' bill would cut "nearly $300 billion from Medicare," distorting the Congressional Budget Office's estimate that the legislation would save the federal government roughly $290 billion over ten years.
The American Prosperity Alliance, a dark money group, is running similarly misleading ads.
Sen. Catherine Cortez Masto (D-Nev.) responded directly to the ads--one of which attacks her directly--in a speech on the Senate floor earlier this week, noting that the 30-second spots led hundreds of constituents to call her office seeking an explanation.
"They were anxious and alarmed over a deliberately misleading ad that is running on TV, on Facebook, and via a text campaign," said Cortez Masto. "In Reno this past weekend, Nevadans came up to me because they were concerned about these false accusations. This ad incorrectly claims that I support a bill that would strip $300 billion dollars from Medicare. This couldn't be further from the truth."
"Powerful interest groups out there don't want this legislation to succeed, so they're pouring dark money into efforts to stop it," the senator continued. "Well, let me just say this: it won't work."
In an analysis of Democrats' proposal published Wednesday, the Kaiser Family Foundation (KFF) concluded that the bill has the potential to "limit annual increases in drug prices for people with Medicare and private insurance" and "provide substantial financial protection to people on Medicare with high out-of-pocket costs."
The precise impact of the legislation, KFF stressed, will depend on which prescription drugs Medicare chooses to negotiate. A separate KFF analysis released last year found that a small number of drugs make up a major share of Medicare's prescription drug spending.
"We are inches from the goal line," David Mitchell, the founder of Patients for Affordable Drugs, tweeted Friday. "We aim to pass reforms to lower Rx prices in the coming days and curb pharma's power to dictate prices to Americans. Let's see it through."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.